Next Article in Journal
A Deep-Sequencing Workflow for the Fast and Efficient Generation of High-Quality African Swine Fever Virus Whole-Genome Sequences
Previous Article in Journal
African Horse Sickness: A Review of Current Understanding and Vaccine Development
Previous Article in Special Issue
Expression of APOBEC3 Lentiviral Restriction Factors in Cats
Open AccessArticle

Follow-Up of Viral Parameters in FeLV- or FIV-Naturally Infected Cats Treated Orally with Low Doses of Human Interferon Alpha

1
Department of Animal Health, Veterinary Faculty, Complutense University of Madrid, 28040 Madrid, Spain
2
Department of Animal Medicine and Surgery, Veterinary Faculty, Complutense University of Madrid, 28040 Madrid, Spain
3
Department of Genetics, Physiology and Microbiology, Faculty of Biology, Complutense University of Madrid, José Antonio Novais, 12, 28040 Madrid, Spain
*
Author to whom correspondence should be addressed.
Viruses 2019, 11(9), 845; https://doi.org/10.3390/v11090845
Received: 5 July 2019 / Revised: 23 August 2019 / Accepted: 8 September 2019 / Published: 11 September 2019
(This article belongs to the Special Issue Feline Viruses and Viral Diseases)
Specific treatments for the long-life infections by feline leukemia virus (FeLV) and feline immunodeficiency virus (FIV) are either toxic, expensive or not too effective. Interferon α (IFN-α) is an immunomodulatory molecule which has been shown in vitro to decrease the release of infective particles. The aim of this study was to follow the progress of the clinical score and viral parameters of FeLV- and FIV-naturally infected privately owned cats treated with recombinant human IFN-α (rHuIFN-α, Roferon-A). Twenty-seven FeLV-infected cats (FeLV+) and 31 FIV-infected cats (FIV+) were enrolled in the study. Owners were instructed to orally administer 1 mL/day of 60 IU rHuIFN-α/mL in alternating weeks for four months. Blood samples were taken at the beginning of the study (M0), mid-treatment (M2), end of treatment (M4), and 6–10 months later (M10). Clinical status at these time points improved notably with rHuIFN-α treatment, regardless of the initial severity of the disease, an effect which lasted throughout the study in most animals (15 of the 16 FeLV+ symptomatic cats; 20 of the 22 FIV+ symptomatic cats) improved markedly their clinical situation. In FeLV+ cats plasma antigenemia (p27CA), reverse transcriptase (RT) activity, and proviral load decreased at M2 and M4 but increased again at M10 (“rebound effect”). The level of antigenemia or RT activity was below the detection limits in FIV+ cats, and the effect on proviral load was less marked than in FeLV+ cats. Taken together, these results indicate that rHuIFN-α is a good candidate for treating FeLV+ cats, but the “rebound effect” seen when treatment was discontinued suggests that additional studies should be conducted to clarify its effect on progression of the infection in cats. View Full-Text
Keywords: feline leukemia virus; FeLV; feline immunodeficiency virus; FIV; treatment; interferon; antigenemia; reverse transcriptase feline leukemia virus; FeLV; feline immunodeficiency virus; FIV; treatment; interferon; antigenemia; reverse transcriptase
Show Figures

Graphical abstract

MDPI and ACS Style

Gomez-Lucia, E.; Collado, V.M.; Miró, G.; Martín, S.; Benítez, L.; Doménech, A. Follow-Up of Viral Parameters in FeLV- or FIV-Naturally Infected Cats Treated Orally with Low Doses of Human Interferon Alpha. Viruses 2019, 11, 845.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map

1
Back to TopTop